Phase I Study of Cisplatin Plus OSI-7904L in Patients With Solid Tumors
Completed
This is a Phase I, open-label, dose escalation, study of the combination of cisplatin and OSI-7904L given on Day 1 every 21 days in patient who have advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/16/2009
Locations: Institute for Drug DevelopmentCancer Therapy & Research Center, San Antonio, Texas
Conditions: Advanced Solid Tumors